OBI Pharma, Inc.

Industry

  • In Vitro Diagnostics
  • Biotechnology
  • Pharmaceuticals

Other Names/Subsidiaries

  • Optimer Biotechnology, Inc.
See more in Biomedtracker

Latest on OBI Pharma, Inc.

Scrip

Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma

 
• By Vibha Ravi, Anju Ghangurde, Joseph Haas, and Ian Haydock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Huadong Pays $20m Up Front For ADCs Fro

Scrip

Siamab, BI Team To ‘Attack’ Potential Of Carbohydrate Antibodies In Cancer

 
• By Joseph Haas

Investigating the potential of carbohydrate antibodies in cancer immunotherapy is an “under-attacked” area, Siamab Therapeutics Inc. CEO Jeff Behrens says, and he thinks his company now has import

In Vivo

Deals Shaping The Medical Industry, July 2017

 
• By Beth Allan, Deanna Kamienski, Maureen Riordan, Steven Muntner, and Amanda Micklus

IN VITRO DIAGNOSTICS Mergers & Acquisitions PerkinElmer Inc. EuroImmun AG PerkinElmer Inc. acquired private German company EuroImmun AG (autoimmune, infectious disease, and allergy testing) fo

Scrip

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

 
• By Joseph Haas, Sukaina Virji, Sten Stovall, Lubna Ahmed, Ian Haydock, and Eleanor Malone

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in